NCT06377683View on ClinicalTrials.gov

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

March 27, 2025

Study Completion Date

March 27, 2025

Conditions
Metastatic Castration-resistant Prostate Cancer, mCRPC
Interventions
DRUG

177Lu-Dansyl-PSMA radioligand therapy

Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.

Trial Locations (1)

361003

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER

NCT06377683 - Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter